Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — H1 2022 Earnings Presentation
24 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, September 2022
Slide 1: 2022 Interim Presentation
2022 Interim Presentation Sep 2022 Strictly Private and Confidential
Slide 2: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 2
Slide 3: Business highlights
CONFIDENTIAL Business highlights In 1H2022, we received 2 NMPA approvals for our flagship products, completed enrollment for 3 registrational clinical trials and obtained the 1st bidding order Note 2 for Toumai® Product Commercialization Laparoscopic Hospital coverage n Toumai®1st Generation receive
Slide 4: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 4
Slide 5: Only surgical robot company covering all major fast-growing surgical specialties
Only surgical robot company world-wide covering all 5 major and fast- CONFIDENTIAL growing surgical specialties 1 2 3 4 5 Laparoscopic Orthopedic Panvascular Natural Orifice Percutaneous China Market US$2,708mm US$593mm US$185mm US$206mm US$348mm Opportunities (2027E) (21A-27E CAGR: 37%) (21A-27E CA
Slide 6: Laparoscopic surgical robot: Flagship product Toumai
Laparoscopic surgical robot CONFIDENTIAL Flagship product – Toumai® Laparoscopic Surgical Robot 2018 Completed the design Toumai® 1st Generation 2018 Admitted to NMPA Green Path First of its kind completed The first Chinese-developed with a Chinese-developed May surgical robot that had completed lap
Slide 7: Toumai 2nd generation registrational clinical trials
Laparoscopic surgical robot (cont’d) CONFIDENTIAL Toumai® 2nd generation – registrational clinical trials Clinical trial centers coverage First and only domestic 2nd globally & 1st Full application of clinical laparoscopic surgical robot domestic laparoscopic specialties to conduct clinical trial su
Slide 8: Toumai 5G ultra remote surgery
Laparoscopic surgical robot (cont’d) CONFIDENTIAL Toumai® – 5G ultra remote surgery Doctors working together 5,000 km apart > 5,000 km Xinjiang Kezhou People’s Hospital Jiangsu Provincial Hospital World's longest distance 5G ultra remote surgery The first 4-arm Laparoscopic Surgical Robot to conduct
Slide 9: Flagship product DFVision 3D Electronic Laparoscope
Laparoscopic surgical robot (cont’d) CONFIDENTIAL Flagship product – DFVision® 3D Electronic Laparoscope n The first Chinese-developed 3D electronic laparoscope admitted to the NMPA Green Path in Apr 2019 n The first surgery completed with Chinese-developed 3D electronic laparoscope in China in Oct
Slide 10: Orthopedic surgical robot: Honghu
Orthopedic surgical robot CONFIDENTIAL Flagship product – Honghu Orthopedic Surgical Robot The only Chinese-developed joint replacement surgical robot with a self-developed robotic arm. The first and only Chinese-developed surgical robot received FDA clearance May Jan Mar Apr Jul 2H 2020 2021 2022 2
Slide 11: Natural Orifice Surgical Robot
CONFIDENTIAL Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Surgery application Product n Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human body and contr
Slide 12: Panvascular Surgical Robot R-ONE
CONFIDENTIAL Panvascular Surgical Robot R-ONE ® Vascular Interventional Surgical Robot R-ONE® Vascular Robot-assisted Interventional Surgical Robot (“R-ONE®”) panvascular surgery CE Marking Surgery application Product n Panvascular surgical robots are used to treat diseases of the vasculature or rel
Slide 13: Percutaneous Surgical Robot Mona Lisa
Percutaneous Surgical Robot CONFIDENTIAL Mona Lisa Robotic Transperineal Prostate Biopsy System iSR’obotTM Mona Lisa Robotic Robot-assisted Transperineal Prostate Biopsy System (“Mona Lisa”) percutaneous surgeries CE Marking Surgery application FDA approval Partner/ Product n Percutaneous surgical r
Slide 14: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 14
Slide 15: Experienced team and well-planned strategies for commercialization
CONFIDENTIAL Experienced team and well-planned strategies for commercialization Specialized Academic promotion / surgeon Increase awareness of surgical Sustainable after-sales commercialization team training and clinical support robots among patients service for hospital n 160+ professionals, coveri
Slide 16: Clear global vision and established footprint
CONFIDENTIAL Clear global vision and established footprint France-based company providing robotic solutions Honghu - First Chinese- Singapore-based company to treat vascular diseases developed surgical which has developed automated China JV shareholding: 51% robot received FDA needle targeting robot
Slide 17: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 17
Slide 18: Breakthrough in the pandemic, continuous funding and adequate cash
CONFIDENTIAL Breakthrough in the pandemic, continuous funding and adequate cash Revenue Operating performance Cash Balance (RMB million) (RMB million) (RMB million) 66% 463.5 1,940.8 1.0 62.8 24% 242.6 1,477.0 14.8 109% 36.2 400.7 191.6 - 21A 1H 22A 1H 21A 1H 22A 1H 21A 22A 1H SBP Listing fee 18
Slide 19: Investment on future – Operating Expenses
CONFIDENTIAL Investment on future – Operating Expenses Invest for sustainable growth Prepare for sales ramp-up Support overall business growth R&D Cost S&M Expenses Administrative Expenses (RMB million) (RMB million) (RMB million) SBP SBP SBP 336.4 110% 41.1 160.1 21.3 295.3 24% 65.1 52.5 338% 64.2
Slide 20: Research and Development Cost
CONFIDENTIAL Research and Development Cost Fund pipeline products Invest in foundation technologies Others Others 18% 18% Orthopedic 336.4m Laparoscopic 336.4m Staff Costs Costs of materials 53% 22% 60% and consumables 29% n Laparoscopic: Toumai®1st received NMPA approval; n Staff Costs, the largest
Slide 21: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 21
Slide 22: Financial Statement – P&L
CONFIDENTIAL Financial Statement – P&L Unit: RMB'000 22A 1H 21A 1H Var. Revenue 1,048 - Cost of sales (357) - Gross profit 691 - Other net income 16,290 15,758 3% Selling and marketing expenses (64,160) (14,657) 338% Administrative expenses (65,139) (52,471) 24% Research and development costs (336,4
Slide 23: Financial Statement – Balance Sheet
CONFIDENTIAL Financial Statement – Balance Sheet Unit: RMB'000 30 Jun 2022 31 Dec 2021 Var. Unit: RMB'000 30 Jun 2022 30 Jun 2022 Var. Non-current assets CAPITAL AND RESERVES Share capital 958,594 958,594 0% Property, plant and equipment 434,893 361,000 20% Reserves 1,033,169 1,434,548 -28% Intangib
Slide 24: Thanks!
CONFIDENTIAL Thanks! 微创机器人 微创机器人 Medbot Surgical (视频号) (服务号) (订阅号)
Shanghai Microport Medbot (Group) — H1 2022 Earnings Presentation on 6ix